Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCOGlobeNewsWire • 04/24/24
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)GlobeNewsWire • 04/22/24
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of InvestorsBusiness Wire • 04/17/24
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 04/13/24
Regeneron (REGN) Accused of Fraudulent Practices Related to EyleaZacks Investment Research • 04/12/24
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?Investors Business Daily • 04/11/24
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to WatchInvestopedia • 04/11/24
US Justice department files complaint against Regeneron, alleges fraudulent drug pricingReuters • 04/10/24
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple MyelomaGlobeNewsWire • 04/07/24
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024GlobeNewsWire • 04/01/24
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript)Seeking Alpha • 03/13/24